DLGAP3 and obsessive-compulsive disorder: People have reported that Dlgap3 and its interaction protein Slc1a1 may serve drug targets of some neuropsychiatric disorders, which are associated with adverse reactions to atypical antipsychotics (AAP), including obsessive-compulsive disorder in schizophrenia [32, 33]